An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
Stopped very slow recruitment rate and a lot of pat. didn't fulfil BCR-ABL requirements
Conditions
Interventions
- DRUG: Imatinib
- DRUG: Nilotinib
Sponsor
Prof. Dr. Nikolas von Bubnoff
Collaborators